. 2019 Dec 7;37(1):501–511. doi: 10.1007/s12325-019-01156-5

Table 3.

Anchored MAIC of apalutamide and enzalutamide

Apalutamide vs. enzalutamide	MAIC-weighted^a
Apalutamide vs. enzalutamide	HR (95% Crl)	P(HR < 1) (%)
Metastasis-free survival
PROSPER definition (112-day cutoff)^b	0.91 (0.68; 1.22)	73.6
SPARTAN definition	0.97 (0.72; 1.29)	59.6
Overall survival	0.77 (0.46; 1.30)	83.5

HR hazard ratio, CrI credible interval, MAIC matching-adjusted indirect comparison

^aSPARTAN patients were matched to PROSPER patients on the following variables: age, PSA and PSA doubling time at baseline, Eastern Cooperative Oncology Group performance status, total Gleason score, use of bone-targeting agents, and history of surgical prostate cancer procedures at baseline

^bFor this analysis, any events occurring after 112 days after treatment discontinuation were censored